They were part of a sophisticated system with prescription drug distributors funneling drugs like oxycodone into Houston pill ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
An experimental GLP-1 obesity drug from Terns Pharmaceuticals led to a 5.5% reduction in body weight in a small study, continuing to build its case as a potential oral alternative to currently ...
Discover how the separation of structurally diverse pharmaceutical drug compounds can be achieved using a PRP-C18 column.
Terns Pharmaceuticals' TERN-601 shows impressive weight loss results in a phase 1 study, positioning TERN competitively in the obesity drug market. The commercial viability of TERN-601's ...
Join Principal Consultant Michael W. Dong of MWD Consulting as he shares his unique perspective on current trends and job opportunities in pharma, the fundamentals of assessing drug quality, and the ...
Atopic dermatitis is treatable with many drugs currently on the market, but many patients find these therapies lacking. The FDA has approved an Eli Lilly drug that offers a new biologic treatment ...
Indies Pharma Jamaica Limited has made history as it became the first Jamaican company to get an ANDA (Abbreviated New Drug Application) approved by the United States Food and Drug Administration ...
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set statistic alerts) please log in with your personal ...
COPENHAGEN, Denmark, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United States Food & Drug Administration (FDA) has granted Orphan Drug ...
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) Wednesday said the Food and Drug Administration or FDA has granted orphan drug designation to the company's drug candidate tebapivat for the ...
London: Terns Pharmaceuticals said its oral obesity drug reduced weight by an average of 4.9 per cent in an early stage study, joining drugmakers vying for a share of the lucrative obesity ...